Monday, October 19, 2026
BTC $81,765 ▼ 0.10%
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
LIVE
ADA$0.217down−0.39%ETH$2,401down−0.19%LINK$11.99down−0.47%SOL$104.82down−0.12%BTC$81,765down−0.10%XRP$1.30down−0.28%S&P 5007,691up+0.41%Nasdaq26,431up+1.11%Dow51,966down−0.07%RUT2,728up+0.25%TNX5.14%up+0.75%TYX5.47%up+0.66%FVX4.93%up+0.61%IRX4.08%up+0.12%VIX18.44down−7.75%GOLD$4,161.10up+0.02%SILVER$57.55up+0.47%OIL$98.96up+0.43%DXY101.83down−0.15%NVDA$217.09up+1.38%AAPL$342.94down−0.15%TSLA$368.06up+3.76%META$705.44down−0.55%MSFT$533.52up+0.84%AMZN$262.45up+4.98%GOOGL$344.18up+1.05%Fear & Greed55 — GreedADA$0.217down−0.39%ETH$2,401down−0.19%LINK$11.99down−0.47%SOL$104.82down−0.12%BTC$81,765down−0.10%XRP$1.30down−0.28%S&P 5007,691up+0.41%Nasdaq26,431up+1.11%Dow51,966down−0.07%RUT2,728up+0.25%TNX5.14%up+0.75%TYX5.47%up+0.66%FVX4.93%up+0.61%IRX4.08%up+0.12%VIX18.44down−7.75%GOLD$4,161.10up+0.02%SILVER$57.55up+0.47%OIL$98.96up+0.43%DXY101.83down−0.15%NVDA$217.09up+1.38%AAPL$342.94down−0.15%TSLA$368.06up+3.76%META$705.44down−0.55%MSFT$533.52up+0.84%AMZN$262.45up+4.98%GOOGL$344.18up+1.05%Fear & Greed55 — Greed
Tag

obesity

2 articles

Viking's Oral VK2735 Hits a Tolerability Wall; Injectable Offers the Real Upside
U.S. Equities9d ago
Viking's Oral VK2735 Hits a Tolerability Wall; Injectable Offers the Real Upside
VKTX's oral weight-loss candidate shows efficacy but high discontinuation rates in Phase 2 trials. The injectable formulation is where the value lies heading into 2027 Phase 3 readout.
Eli Lilly's Retatrutide Shows 20.8% Weight Loss at Top Dose; BLA Due Q1 2027
U.S. Equities20d ago
Eli Lilly's Retatrutide Shows 20.8% Weight Loss at Top Dose; BLA Due Q1 2027
Triple agonist achieves dose-dependent weight reductions up to 49.6 pounds and A1C drops to 5.7% in 40% of patients, clearing path for 2027 market entry.